Across TCGA pan-cancer cohorts, CBLL2 RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of CBLL2’s most consistent transcriptional readouts.
The strongest signal is observed in lung adenocarcinoma (LUAD), where CBLL2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types CBLL2 is over-expressed in tumor.
LUAD are the cancer types where CBLL2 tumor–normal differential expression is most reproducible.